Genenta Science S.p.A. (GNTA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 22, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Apr 1, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GNTA SEC filings page.
This page shows Genenta Science S.p.A. (GNTA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Genenta Science S.p.A. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Genenta Science S.p.A. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Genenta Science S.p.A. reported a net loss of $7.7M while operations used $8.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Genenta Science S.p.A.'s EBITDA was -$7.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
Genenta Science S.p.A. reported a net loss of $7.7M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Genenta Science S.p.A. earned -$0.39 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Genenta Science S.p.A. recorded an outflow of $8.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
Genenta Science S.p.A. held $6.5M in cash against $8.9M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Genenta Science S.p.A.'s ROE was -29.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 41.4 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Genenta Science S.p.A. invested $3.2M in research and development in fiscal year 2025. This represents a decrease of 36.4% from the prior year.
Genenta Science S.p.A. invested $9K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 93.5% from the prior year.
Not reported for fiscal year 2025.
GNTA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F |
|---|---|---|---|---|---|---|---|
| R&D Expenses | $3.2M-36.4% | $5.0M-30.7% | $7.2M+25.9% | $5.7M+48.8% | $3.8M-33.1% | $5.7M+37.9% | $4.2M |
| SG&A Expenses | $4.6M-10.6% | $5.1M-11.9% | $5.8M-4.7% | $6.1M+134.8% | $2.6M+135.7% | $1.1M+6.6% | $1.0M |
| Operating Income | -$7.8Mn/m | -$10.1Mn/m | -$13.0Mn/m | -$11.8Mn/m | -$6.4Mn/m | -$6.8Mn/m | -$5.2M |
| EBITDA | -$7.7Mn/m | -$10.1Mn/m | -$12.9Mn/m | -$11.8Mn/m | -$6.4Mn/m | -$6.8M | N/A |
| Net Income | -$7.7Mn/m | -$9.2Mn/m | -$12.9Mn/m | -$9.1Mn/m | -$6.3Mn/m | -$6.8Mn/m | -$5.2M |
| EPS (Basic) | N/A | N/A | -$0.71n/m | -$0.50n/m | -$0.42 | N/A | N/A |
| EPS (Diluted) | -$0.39n/m | -$0.51n/m | -$0.71n/m | -$0.50n/m | -$0.42 | N/A | N/A |
| Diluted Shares (Avg) | 20M+7.9% | 18M+0.3% | 18M0.0% | 18M+20.8% | 15M | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
GNTA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F |
|---|---|---|---|---|---|---|---|
| Total Assets | $37.4M+143.9% | $15.3M-37.9% | $24.7M-30.9% | $35.8M-21.0% | $45.3M+111.6% | $21.4M | N/A |
| Current Assets | $35.2M+134.9% | $15.0M-36.3% | $23.5M-30.7% | $33.9M-22.6% | $43.9M+116.9% | $20.2M | N/A |
| Cash & Equivalents | $6.5M+36.8% | $4.7M+16.1% | $4.1M-87.2% | $31.9M-24.4% | $42.1M+122.8% | $18.9M | N/A |
| Short-Term Investments | $26.5M+217.5% | $8.4M-49.9% | $16.7Mn/m | $0n/m | $0n/m | $0 | N/A |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 | N/A |
| Total Liabilities | $11.8M+389.3% | $2.4M+13.8% | $2.1M-13.9% | $2.5M+86.5% | $1.3M-54.1% | $2.9M | N/A |
| Current Liabilities | $2.5M+14.4% | $2.2M+13.2% | $1.9M-17.8% | $2.3M+81.8% | $1.3M-55.0% | $2.9M | N/A |
| Non-Current Liabilities | $9.3M+3827.9% | $237K+19.5% | $198K+59.5% | $124K+258.7% | $35K+63.0% | $21K | N/A |
| Long-Term Debt | $8.9M | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $25.6M+98.2% | $12.9M-42.8% | $22.6M-32.1% | $33.3M-24.3% | $44.0M+137.4% | $18.5M-12.4% | $21.2M |
| Retained Earnings | -$73.5Mn/m | -$58.0Mn/m | -$52.1Mn/m | -$37.9Mn/m | -$30.6Mn/m | -$26.3M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
GNTA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.1Mn/m | -$6.5Mn/m | -$12.4Mn/m | -$7.9Mn/m | -$7.9Mn/m | -$7.4Mn/m | -$2.8M |
| Depreciation & Amortization | $33K-28.5% | $46K-1.9% | $47K+614.9% | $7K+18.7% | $6K+138.1% | $2K | N/A |
| Stock-Based Compensation | $1.2M+35.1% | $877K+7.2% | $818K+5.9% | $773K+37.4% | $563K0.0% | $563K-33.1% | $841K |
| Capital Expenditures | $9K+93.5% | $5K-69.7% | $15K-47.3% | $29K+184.0% | $10K-60.1% | $26K | N/A |
| Free Cash Flow | -$8.1Mn/m | -$6.5Mn/m | -$12.4Mn/m | -$8.0Mn/m | -$7.9Mn/m | -$7.4M | N/A |
| Investing Cash Flow | -$17.1M-339.6% | $7.1Mn/m | -$16.5Mn/m | -$29Kn/m | -$10Kn/m | -$26K | N/A |
| Financing Cash Flow | $26.2M+9228.5% | $280K+47635.2% | $587 | N/A | $32.5M+1814.5% | $1.7M-89.8% | $16.6M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
GNTA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F |
|---|---|---|---|---|---|---|---|
| Return on Equity | -29.9%+41.4pp | -71.3%-14.3pp | -57.0%-29.8pp | -27.2%-13.0pp | -14.2%+22.7pp | -36.9%-12.5pp | -24.4% |
| Return on Assets | -20.5%+39.6pp | -60.1%-8.0pp | -52.1%-26.8pp | -25.4%-11.5pp | -13.8%+18.1pp | -31.9% | N/A |
| Current Ratio | 14.16+7.3x | 6.89-5.4x | 12.25-2.3x | 14.53-19.6x | 34.15+27.1x | 7.09 | N/A |
| Debt-to-Equity | 0.35 | N/A | N/A | N/A | N/A | N/A | N/A |
| Liabilities-to-Equity | 0.46+0.3x | 0.19+0.1x | 0.090.0x | 0.070.0x | 0.03-0.1x | 0.16 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Genenta Science S.p.A. GNTA | FY2025 | N/A | -$7.7M | N/A | $30.4M | — |
| vTv Therapeutics Inc. VTVT | FY2025 | $0 | -$27.0M | N/A | $107.4M | — |
| Actinium Pharmaceuticals, Inc ATNM | FY2025 | $90K | -$33.9M | N/A | $50.3M | — |
| INmune Bio Inc. INMB | FY2025 | $50K | -$45.9M | N/A | $42.7M | — |
| PDS Biotechnology Corporation PDSB | FY2025 | N/A | -$34.5M | N/A | $84.1M | — |
| PolyPid Ltd. PYPD | FY2025 | N/A | -$34.2M | N/A | $104.2M | — |
Where Genenta Science S.p.A. Ranks
Frequently Asked Questions
Is Genenta Science S.p.A. profitable?
No, Genenta Science S.p.A. (GNTA) reported a net loss of $7.7M in fiscal year 2025.
What is Genenta Science S.p.A.'s EBITDA?
Genenta Science S.p.A. (GNTA) had EBITDA of -$7.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Genenta Science S.p.A. have?
As of fiscal year 2025, Genenta Science S.p.A. (GNTA) had $6.5M in cash and equivalents against $8.9M in long-term debt.
What is Genenta Science S.p.A.'s return on equity (ROE)?
Genenta Science S.p.A. (GNTA) has a return on equity of -29.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Genenta Science S.p.A.'s free cash flow?
Genenta Science S.p.A. (GNTA) recorded an outflow of $8.1M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Genenta Science S.p.A.'s operating cash flow?
Genenta Science S.p.A. (GNTA) recorded an outflow of $8.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Genenta Science S.p.A.'s total assets?
Genenta Science S.p.A. (GNTA) had $37.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Genenta Science S.p.A.'s capital expenditures?
Genenta Science S.p.A. (GNTA) invested $9K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Genenta Science S.p.A. spend on research and development?
Genenta Science S.p.A. (GNTA) invested $3.2M in research and development during fiscal year 2025.
What is Genenta Science S.p.A.'s current ratio?
Genenta Science S.p.A. (GNTA) had a current ratio of 14.16 as of fiscal year 2025, which is generally considered healthy.
What is Genenta Science S.p.A.'s debt-to-equity ratio?
Genenta Science S.p.A. (GNTA) had a debt-to-equity ratio of 0.35 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is Genenta Science S.p.A.'s liabilities-to-equity ratio?
Genenta Science S.p.A. (GNTA) had a liabilities-to-equity ratio of 0.46 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is Genenta Science S.p.A.'s return on assets (ROA)?
Genenta Science S.p.A. (GNTA) had a return on assets of -20.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Genenta Science S.p.A.'s P/E ratio?
Genenta Science S.p.A. (GNTA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $30.4M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Genenta Science S.p.A.'s price-to-sales ratio?
Genenta Science S.p.A. (GNTA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $30.4M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Genenta Science S.p.A.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Genenta Science S.p.A. (GNTA) held $33.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.1M over that year. Dividing the one by the other, the reported balance equals about 49 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Genenta Science S.p.A.'s Piotroski F-Score?
Genenta Science S.p.A. (GNTA) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Genenta Science S.p.A.'s earnings high quality?
Genenta Science S.p.A. (GNTA) reported a net loss of $7.7M while operations used $8.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.